Episode
Aehr Test Systems (AEHR): We Called the $60M Stock Raise — Here's What Investors Need to Know Now
- Podcast
- Chip Stock Investor Podcast
- Published
- Apr 22, 2026
- Duration seconds
- 454
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/chip-stock-investor-podcast-6441813/episodes/aehr-test-systems-aehr-we-called-the-60m-stock-raise-here-s-what-investors-need-to-know-now/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/chip-stock-investor-podcast-6441813/aehr-test-systems-aehr-we-called-the-60m-stock-raise-here-s-what-investors-need-to-know-now.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We've been following Aehr Test Systems since late 2022. We watched it run from a micro-cap to a $3 billion market cap on the back of AI accelerator hype — and we called what was coming next.In this episode, Nick walks through the full picture on Aehr Test Systems (AEHR): what the business actually does today, why the valuation has dramatically outpaced the fundamentals, and why management issuing $60 million worth of new stock into the market is exactly the signal investors needed to see.The core tension is straightforward but important. Aehr's InCal acquisition was genuinely smart — it diversified the business away from pure silicon carbide and EV testing into AI accelerator burn-in, likely serving Google's TPU supply chain through a subcontractor. Growth is returning. But the stock already reflects a massive, multi-year recovery in a single move. With quarterly revenue of just $10 million and fiscal 2027 guidance that implies somewhere between $50–100 million in annual revenue, a $2.5–3 billion market cap is pricing in a lot of optimism that hasn't been earned yet.This is a pattern CSI has seen before with Aehr — almost identically in mid-2023 during the silicon carbide and EV cycle peak. The key difference this time is that AI data center demand is likely more durable than EV was. But that doesn't mean the stock can't get ahead of itself in the meantime.The $60M ATM raise is management's way of saying: we agree the stock is ahead of our near-term guidance, and we're going to take advantage of that. It's not a death knell for the company. It is a clear signal about where we are in the cycle.What we cover:— Aehr's business today: silicon carbide, AI accelerator testing, and the InCal acquisition— Why $10M/quarter in revenue doesn't support a $3B market cap — yet— The…